Article
Apolipoprotein E genotypes as predictors of high-risk groups for developing hyperlipidemia in kidney transplant recipients undergoing sirolimus treatment.
Transplantation - 27 Dec 2005
Maluf Daniel G, Mas Valeria R, Archer Kellie J, Yanek Kenneth, King Anne, Ferreira-Gonzalez Andrea, Fisher Robert A, Posner Marc
Abstract excerpt
BACKGROUND: Hypercholesterolemia (HCHL) and hypertriglyceridemia (HTRG) have emerged as the most significant metabolic consequences of therapy with sirolimus. Lipid status can be exacerbated by a variety of factors in the posttransplant setting, including genetic factors. Apoliprotein E (Apo E) polymorphism is an established genetic risk factor for hyperlipidemia. We studied the association between Apo E gene...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.